Luc Wasungu

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

Patrick W. Serruys, Bernard Chevalier, Dariusz Dudek et al. · The Lancet · 2014 · 560 citations · Full text

Medicine, Cardiology, Surgery +17

A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis

Patrick W. Serruys, John Ormiston, Robert‐Jan van Geuns et al. · Journal of the American College of Cardiology · 2016 · 160 citations · Full text

Medicine, Bioengineering, Cardiology +14

Interference of poly(ethylene glycol)–lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions

Fuxin Shi, Luc Wasungu, Anita Nomden et al. · Biochemical Journal · 2002 · 148 citations · Full text

Pharmacy, Molecular Biology, Pharmaceutics +17

Antitumor drug delivery in multicellular spheroids by electropermeabilization

Laure Gibot, Luc Wasungu, Justin Teissié et al. · Journal of Controlled Release · 2013 · 76 citations

Pharmacy, Bioengineering, Pharmaceutics +13

Lipoplexes formed from sugar-based gemini surfactants undergo a lamellar-to-micellar phase transition at acidic pH. Evidence for a non-inverted membrane-destabilizing hexagonal phase of lipoplexes

Luc Wasungu, Marc C. A. Stuart, Marco Scarzello et al. · Biochimica et Biophysica Acta (BBA) - Biomembranes · 2006 · 61 citations · Full text

Natural Sciences, Biochemistry, Biophysics +17